Search

Merck, known as MSD outside of the United States and Canada, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending [...]

Merck, known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive [...]

Merck, known as MSD outside of the United States and Canada, announced that new clinical and real-world data for the company's 9-valent Human Papillomavirus (HPV) vaccine, Gardasil 9 (Human Papillomavirus [...]

Merck, known as MSD outside of the U.S. and Canada, reported that the European Commission (EC) has approved two new indications for KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in gynecologic cancers. [...]

Merck, known as MSD outside of the United States and Canada, reported that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) voted to [...]

Byline: Rahway Merck, known as MSD outside of the United States and Canada, announced that the US Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) [...]

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved two new indications for Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in gynaecologic [...]

Merck, known as MSD outside of the United States and Canada, reported that the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, as a perioperative treatment for patients [...]

Exelixis, Inc. and Merck, known as MSD outside of the United States and Canada, announced that the companies have entered into a clinical development collaboration to evaluate the combination of [...]

Merck, known as MSD outside of the United States and Canada, reported that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions recommending approval [...]

Merck, known as MSD outside of the United States and Canada, announced that new data highlighting the long-term efficacy and safety of tulisokibart (MK-7240), an investigational humanized monoclonal antibody directed [...]

Merck, known as MSD outside of the United States and Canada, announced the US Food and Drug Administration (FDA) has approved Keytruda, Merck's anti-PD-1 therapy, in combination with pemetrexed and [...]

Merck, known as MSD outside of the United States and Canada, announced the first-time presentation of overall survival (OS) results from the phase 3 KEYNOTE-522 trial evaluating Keytruda (pembrolizumab), Merck's [...]

Merck, known as MSD outside of the United States and Canada, announced overall survival (OS) results from the final analysis of the phase 3 KEYNOTE-811 trial evaluating Keytruda (pembrolizumab), Merck's [...]

Merck, known as MSD outside of the United States and Canada, provided updates on two phase 3 trials, KEYNOTE-867 and KEYNOTE-630. Merck is discontinuing the phase 3 KEYNOTE-867 trial evaluating [...]

Merck, known as MSD outside of the United States and Canada, reported that the European Commission (EC) has approved WINREVAIR (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies, [...]

Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, reported they have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody [...]

Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the phase 3 KeyVibe-008 trial based on the recommendation of an independent Data Monitoring Committee [...]

Merck announced the discontinuation of the Phase 3 KeyVibe-008 trial based on the recommendation of an independent Data Monitoring Committee. The trial is evaluating the investigational fixed-dose combination of vibostolimab, [...]

Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody-drug conjugates to [...]

Moderna, Inc. and Merck, known as MSD outside of the United States and Canada, announced the first presentation of results from a planned analysis from the phase 2b randomized KEYNOTE-942/mRNA-4157-P201 [...]

Merck, known as MSD outside of the United States and Canada, has reported the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial. Merck said [...]

Merck, known as MSD outside of the United States and Canada, announced that new data for four approved oncology medicines and four pipeline candidates in more than 25 types of [...]

Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the phase 3 KeyVibe-010 trial. The trial is [...]

Positive findings were announced from a phase 3 trial comparing Merck’s investigational 21-valent pneumococcal conjugate vaccine, V116, to pneumococcal 23-valent polyvalent vaccine (PPSV23) in pneumococcal vaccine-naïve adults. The double-blind, active [...]

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved Keytruda, Merck's anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant [...]

Merck, known as MSD outside of the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved sotatercept-csrk (US Brand Name: Winrevair, for injection, 45mg, [...]

Merck, known as MSD outside of the United States and Canada, announced that the phase 3 KEYLYNK-006 trial evaluating Keytruda, Merck's anti-PD-1 therapy, in combination with maintenance Lynparza, a PARP [...]

Merck announced positive data from multiple Phase 3 studies evaluating V116, the company's investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 13th Meeting of the International Society of Pneumonia and [...]

Merck, known as MSD outside of the United States and Canada, announced that the phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating Keytruda, Merck's anti-PD-1 therapy, in combination with [...]

Merck announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemoradiotherapy met its primary endpoint of overall survival for the [...]

The CDC's Advisory Committee on Immunization Practices (ACIP) has announced several updates following its most recent meeting, held June 26 to 28, 2024. Read on for the latest, including updates [...]

Merck, known as MSD outside of the United States and Canada, announced the US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application [...]

Merck, known as MSD outside of the United States and Canada, announced results from the phase 3 AMBASSADOR (A031501)/KEYNOTE-123 trial evaluating Keytruda, Merck's anti-PD-1 therapy, for the adjuvant treatment of [...]

Merck, known as MSD outside of the United States and Canada, announced the US Food and Drug Administration (FDA) has approved Keytruda, Merck's anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) [...]

Merck, known as MSD outside of the United States and Canada, announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Merck's New [...]